Loading…
Sectoral / Thematic · Nippon India Mutual Fund · AMFI code 102431Nippon India Pharma Fund
Disclosed for 84 months, Sep 2019 to Aug 2026.Published as: NIPPON INDIA PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹8,306 Cr
up ₹431 Cr vs Jan 2026
- Stocks held
- 35
- unchanged
- Top 10 weight
- 58.4%
- of the portfolio in its ten largest
- Cash & debt
- 0.3%
- cash, money market and debt
- Moves this month
- 0 in · 0 out
- added to 10, trimmed 12
Nippon India Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In February 2026 it disclosed 35 stocks worth ₹8,306 Cr, up ₹431 Cr from Jan 2026. Its largest positions were Sun Pharmaceutical Industries Limited (13.1%), Lupin Limited (8.0%), Divi's Laboratories Limited (6.6%); the ten largest together made up 58.4% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 74.2% of its equity. Cash and debt stood at 0.3%. Compared with Jan 2026 the fund entered 0 new stocks and exited 0.
Against 226 other Sectoral / Thematic funds
Concentration
80%
Top-10 weight is higher than 80% of peers
Breadth
26%
Holds more stocks than 26% of peers
Cash
4%
Holds more cash than 4% of peers
Holdings in February 2026
Download CSVEvery line the fund disclosed, with the change against Jan 2026. Click a column to sort; click a company to see every fund that owns it.
- Weight
- 13.08%
- Δ weight
- up 0.41 pts
- Value
- ₹1,087 Cr
- Δ value
- up ₹88.7 Cr
- Status
- Added
- Weight
- 7.99%
- Δ weight
- up 0.11 pts
- Value
- ₹664 Cr
- Δ value
- up ₹43 Cr
- Status
- Added
- Weight
- 6.56%
- Δ weight
- up 0.03 pts
- Value
- ₹545 Cr
- Δ value
- up ₹30.4 Cr
- Status
- Added
- Weight
- 5.81%
- Δ weight
- down 0.25 pts
- Value
- ₹482 Cr
- Δ value
- up ₹5.3 Cr
- Status
- Added
- Weight
- 5.67%
- Δ weight
- down 0.20 pts
- Value
- ₹471 Cr
- Δ value
- up ₹8.5 Cr
- Status
- Added
- Weight
- 5.17%
- Δ weight
- down 0.57 pts
- Value
- ₹429 Cr
- Δ value
- down ₹22.4 Cr
- Status
- Trimmed
- Weight
- 3.70%
- Δ weight
- up 0.02 pts
- Value
- ₹307 Cr
- Δ value
- up ₹17.6 Cr
- Status
- Added
- Weight
- 3.49%
- Δ weight
- up 1.99 pts
- Value
- ₹290 Cr
- Δ value
- up ₹171 Cr
- Status
- Added
- Weight
- 3.49%
- Δ weight
- down 0.02 pts
- Value
- ₹290 Cr
- Δ value
- up ₹13.2 Cr
- Status
- Added
- Weight
- 3.41%
- Δ weight
- up 0.02 pts
- Value
- ₹283 Cr
- Δ value
- up ₹16.4 Cr
- Status
- Added
- Weight
- 3.07%
- Δ weight
- up 0.36 pts
- Value
- ₹255 Cr
- Δ value
- up ₹41.7 Cr
- Status
- Added
- Weight
- 3.06%
- Δ weight
- up 0.61 pts
- Value
- ₹254 Cr
- Δ value
- up ₹61.6 Cr
- Status
- Added
- Weight
- 2.83%
- Δ weight
- up 0.04 pts
- Value
- ₹235 Cr
- Δ value
- up ₹15.5 Cr
- Status
- Added
- Weight
- 2.51%
- Δ weight
- down 0.04 pts
- Value
- ₹209 Cr
- Δ value
- up ₹7.9 Cr
- Status
- Added
- Weight
- 2.50%
- Δ weight
- down 0.11 pts
- Value
- ₹208 Cr
- Δ value
- up ₹2.2 Cr
- Status
- Added
- Weight
- 2.37%
- Δ weight
- down 0.23 pts
- Value
- ₹197 Cr
- Δ value
- down ₹7.7 Cr
- Status
- Trimmed
- Weight
- 2.20%
- Δ weight
- down 0.14 pts
- Value
- ₹183 Cr
- Δ value
- down ₹1.2 Cr
- Status
- Trimmed
- Weight
- 2.08%
- Δ weight
- down 0.26 pts
- Value
- ₹173 Cr
- Δ value
- down ₹11.6 Cr
- Status
- Trimmed
- Weight
- 2.05%
- Δ weight
- down 0.13 pts
- Value
- ₹171 Cr
- Δ value
- down ₹1.2 Cr
- Status
- Trimmed
- Weight
- 1.98%
- Δ weight
- down 0.40 pts
- Value
- ₹164 Cr
- Δ value
- down ₹22.7 Cr
- Status
- Trimmed
- Weight
- 1.94%
- Δ weight
- up 0.10 pts
- Value
- ₹161 Cr
- Δ value
- up ₹15.9 Cr
- Status
- Added
- Weight
- 1.82%
- Δ weight
- down 0.26 pts
- Value
- ₹151 Cr
- Δ value
- down ₹12.5 Cr
- Status
- Trimmed
- Weight
- 1.76%
- Δ weight
- down 0.12 pts
- Value
- ₹146 Cr
- Δ value
- down ₹2 Cr
- Status
- Trimmed
- Weight
- 1.31%
- Δ weight
- down 0.08 pts
- Value
- ₹109 Cr
- Δ value
- down ₹62 L
- Status
- Trimmed
- Weight
- 1.27%
- Δ weight
- down 0.04 pts
- Value
- ₹106 Cr
- Δ value
- up ₹2.1 Cr
- Status
- Added
- Weight
- 1.25%
- Δ weight
- up 0.06 pts
- Value
- ₹104 Cr
- Δ value
- up ₹10.1 Cr
- Status
- Added
- Weight
- 1.15%
- Δ weight
- up <0.01 pts
- Value
- ₹95.9 Cr
- Δ value
- up ₹5.2 Cr
- Status
- Added
- Weight
- 1.10%
- Δ weight
- down 0.08 pts
- Value
- ₹91.3 Cr
- Δ value
- down ₹1.2 Cr
- Status
- Trimmed
- Weight
- 1.04%
- Δ weight
- up 0.01 pts
- Value
- ₹86.5 Cr
- Δ value
- up ₹5.1 Cr
- Status
- Added
- Weight
- 0.96%
- Δ weight
- down 0.17 pts
- Value
- ₹79.5 Cr
- Δ value
- down ₹9.7 Cr
- Status
- Trimmed
- Weight
- 0.89%
- Δ weight
- up 0.09 pts
- Value
- ₹74.2 Cr
- Δ value
- up ₹10.8 Cr
- Status
- Added
- Weight
- 0.89%
- Δ weight
- up 0.04 pts
- Value
- ₹74 Cr
- Δ value
- up ₹7.4 Cr
- Status
- Added
- Weight
- 0.67%
- Δ weight
- down 0.01 pts
- Value
- ₹55.4 Cr
- Δ value
- up ₹1.9 Cr
- Status
- Added
- Weight
- 0.45%
- Δ weight
- down 0.06 pts
- Value
- ₹37.1 Cr
- Δ value
- down ₹2.8 Cr
- Status
- Trimmed
- Cash, TREPS & receivables
- Weight
- 0.30%
- Δ weight
- down 0.73 pts
- Value
- ₹25.3 Cr
- Δ value
- down ₹56 Cr
- Status
- Trimmed
- Weight
- 0.16%
- Δ weight
- down <0.01 pts
- Value
- ₹13.6 Cr
- Δ value
- up ₹51 L
- Status
- Added
What changed, Jan 2026 to Feb 2026
New New positions (0)
None.
Exited Exited (0)
None.
Added Biggest additions
- Max Healthcare Institute Limitedup ₹171 Cr (+1.99% pts)
- Sun Pharmaceutical Industries Limitedup ₹88.7 Cr (+0.41% pts)
- Mankind Pharma Limitedup ₹61.6 Cr (+0.61% pts)
- Lupin Limitedup ₹43 Cr (+0.11% pts)
- Sai Life Sciences Limited ₹41.7 Cr (+0.36% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Jan 2026, the weight rose most in Healthcare Services (+0.4 pts), and fell most in Pharmaceuticals & Biotechnology (−0.4 pts).
- Healthcare Services21.2% → 21.7%+0.4 pts
- Pharmaceuticals & Biotechnology74.6% → 74.2%−0.4 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Feb 2023 | Feb 2025 | Aug 2025 | Nov 2025 | Jan 2026 | Feb 2026 |
|---|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 76.8% | 78.3% | 75.5% | 75.2% | 74.6% | 74.2% |
| Healthcare Services | 19.7% | 17.7% | 20.2% | 20.8% | 21.2% | 21.7% |
| Retailing | 1.6% | 3.4% | 3.7% | 3.5% | 3.7% | 3.7% |
| Pharmaceuticals | 1.6% | 0.5% | 0.6% | 0.6% | 0.5% | 0.4% |
Allocation in Feb 2026change vs Jan 2026
- Pharmaceuticals & Biotechnology (24)74.2%▼ 0.4 pts
- Healthcare Services (9)21.7%▲ 0.4 pts
- Retailing (1)3.7%
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal.
Cash & debt, Feb 2026
0.3%
▼ 0.7 pts vs Jan 2026
- Cash alone
- 0.3%
- cash and net receivables
- A year earlier
- 1.1%
- Feb 2025 · now ▼ 0.8 pts
- Last 12 months
- 0.3% – 2.6%
- lowest to highest · record 5.9% in May 2021
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.